Dan Luo

Title: Dan Luo - Innovator in Monoclonal Antibody Development

Introduction

Dan Luo is a prominent inventor based in Chengdu, China. He has made significant contributions to the field of immunology through his innovative work on monoclonal antibodies. His research focuses on developing specific antibodies that can enhance diagnostic accuracy in medical applications.

Latest Patents

Dan Luo holds 2 patents, one of which is titled "Anti-CD79B protein monoclonal antibody, products containing the same, and uses thereof." This patent discloses an anti-CD79B protein monoclonal antibody that comprises a heavy chain and a light chain. The heavy chain includes a heavy chain variable region, while the light chain includes a light chain variable region. The heavy chain variable region contains complementary-determining regions CDR1, CDR2, and CDR3 with specific amino acid sequences. Similarly, the light chain variable region comprises complementary-determining regions CDR1, CDR2, and CDR3 with distinct amino acid sequences. This antibody exhibits high specificity and sensitivity, allowing for the precise recognition of cells expressing the CD79B protein. It is particularly suitable for immunological detection, effectively reducing false-positive and false-negative results in assays, thereby improving diagnostic outcomes.

Career Highlights

Dan Luo is affiliated with the Sichuan Cancer Hospital, where he continues to advance his research in the field of cancer diagnostics. His work has garnered attention for its potential to improve patient outcomes through more accurate detection methods.

Collaborations

Dan collaborates with notable colleagues, including Tongyu Lin and Yang Liu, who contribute to his research efforts and enhance the impact of his innovations.

Conclusion

Dan Luo's contributions to the development of monoclonal antibodies represent a significant advancement in immunological diagnostics. His innovative work continues to pave the way for improved medical applications and patient care.